Oncology Today with Dr Neil Love

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3

AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

ER-Positive, HER2-Positive Metastatic Breast Cancer — Patterns of Care Among Community Oncologists

Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program

Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer — An Interview with Prof Ticiana Leal

Lambert-Eaton Myasthenic Syndrome (LEMS) represents a critical paraneoplastic manifestation in patients with small cell lung cancer, characterized by autoantibodies that disrupt calcium ion influx at the presynaptic nerve terminal. Clinical identification relies on recognizing the triad of proximal muscle weakness, dys...

For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress

Metastatic Triple-Negative Breast Cancer — Patterns of Care

Metastatic triple-negative breast cancer management has shifted from standard chemotherapy to TROP2-directed antibody-drug conjugates (ADCs), significantly extending survival and response durations. Clinical strategies now prioritize these ADCs, such as Sacituzumab Govitecan and Dato-DXD, even in heavily pre-treated se...

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

Recent clinical developments in non-Hodgkin lymphoma emphasize a transition toward personalized, less toxic treatment paradigms. In Diffuse Large B-Cell Lymphoma, the integration of novel agents like antibody-drug conjugates and bispecific antibodies challenges traditional chemotherapy standards, with ongoing research ...

For Oncology Nurses: Pancreatic Cancer — Proceedings from the 2026 Annual ONS Congress

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway

PI3K, AKT, and mTOR pathway inhibitors represent a rapidly evolving treatment landscape for hormone receptor-positive metastatic breast cancer. Recent clinical data highlights the efficacy of agents like Gedatolisib, which targets both PI3K and mTOR, alongside established therapies such as Capivasertib and Alpelisib. M...

AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Gastroesophageal Cancers — Year in Review Series on Relevant New Datasets and Advances

Gastroesophageal cancer management increasingly relies on precise biomarker assessment—specifically MSI-high status, HER2, PD-L1, and Claudin 18.2—to guide therapeutic selection. In locally advanced MSI-high disease, dual checkpoint inhibitor therapy demonstrates high pathologic complete response rates, suggesting pote...

Genitourinary Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Metastatic Bladder Cancer — Rapid Case Review Issue 6

For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress

Metastatic Bladder Cancer — Rapid Case Review Issue 5